Included in the formulation
АТХ:D.01.A.C Imidazole derivatives
D.01.A.C.12 Fenticonazole
Pharmacodynamics:Antifungal agent.
The imidazole derivative exhibits an antifungal effect by blocking the biosynthesis of the ergosterol of the fungal cell membrane. "Target" for the action of the drug is the enzyme 14-α-demethylase.
14-α-demethylase is part of a group of enzymes known collectively cytochrome P450. All enzymes of the cytochrome P450 group contain a hematinic iron-containing pigment. Fenticonazole binds to the iron atom of the hematinic group and inactivates 14-α-demethylase, which leads to a disruption in the synthesis of ergosterol and the accumulation of lanosterol and other sterols. Their incorporation into the membrane instead of ergosterol significantly disrupts the structure and function of the fungal cell membrane.
The decrease in the synthesis of ergosterol, as well as the accumulation of 14α-methylsterols, destroys the densely packed acyl chains of the phospholipids of the fungal membranes. Destabilization of the fungal membrane leads to dysfunction of membrane enzymes, including those involved in the electron transport chain, and ultimately to cell death.
It is active against Candida spp. (including Candida albicans) and Gram-positive bacteria (Staphylococcus aureus, Streptococcus spp.), as well as against Trichomonas vaginalis.
Unlike other known azole compounds fenticonazole inhibits the biosynthesis of proteases of Candida spp. at concentrations below the minimum suppressive level - from 0.25 to 16 μg / ml. This action does not depend on the magnitude of antimycotic activity and is due to the inhibition of one of the stages of the formation of proteolytic enzymes by yeast-like fungi.
Pharmacokinetics:Virtually does not undergo systemic absorption. The degree of absorption through the mucous membranes is extremely low.
Indications:Vaginal trichomoniasis, vulvovaginalth candidiasis.
I.A50-A64.A59.0 Urogenital trichomoniasis
I.B35-B49.B37.3 Candidiasis of the vulva and vagina (N77.1 *)
I.B35-B49.B37.4 Candidiasis of other urogenital localizations
XIV.N70-N77.N77.1 * Vaginitis, vulvitis and vulvovaginitis in infectious and parasitic diseases classified elsewhere
Contraindications:For cream: hypersensitivity, pregnancy (I trimester).
For capsules of vaginal: hypersensitivity, pregnancy, lactation, children's age. The drug can not be administered during the treatment.
Pregnancy and lactation:Data on efficacy and safety of use during pregnancy and lactation are not available.The use in the first trimester of pregnancy and during lactation is contraindicated.
Dosing and Administration:Intravaginal. Cream 2% (approximately 5 g) is injected deep into the vagina once a day, in the evening or, if necessary, 2 times a day (morning and evening). Treatment is carried out until complete clinical recovery (usually 3-6 days). The second course is 10 days later.
One capsule (600 mg or 1000 mg) is injected deep into the vagina in the prone position before going to bed once. If necessary, re-use after 3 days.
Side effects:Allergic reactions: rarely - hives, rashes, erythema.
Local reactions: burning, itching, irritation in the place of application.
Interaction:The interaction of fenticonazole in the form of a cream or capsules for intravaginalabout the use with other medicines is not described.
Special instructions:Can not be used during menstruation. During treatment, you should not wash your vagina. In the future, use neutral or slightly alkaline soap.
With prolonged use, it is possible to develop sensitization. In this case, it is necessary to stop treatment and consult a doctor.If the symptoms do not disappear within 3 weeks of use, the diagnosis should be verified.
To avoid re-infection, simultaneous treatment of sexual partners is recommended.